0 Items
Select Page

Parvovirus

For most healthy people, parvovirus B19 infection causes a mild, self-limiting illness which is followed by life-long immunity. Infection is common in developed countries, where approximately 15% of pre-school children, 50% of adults, and 85% of elderly people show evidence of past infection.

The Native Antigen Company offers recombinant Parvovirus virus-like particles, expressing VP2 antigen in support of research into parvovirus biology and infection.

Parvovirus Background

Parvovirus B19 (B19V) is a small, non-enveloped, single-stranded DNA virus. Parvovirus belongs to the genus Erythroparvovirus within the Parvovirinae subfamily and is a member of the Parvoviridae family of viruses. B19V is highly infectious and is commonly transmitted between humans via infected respiratory secretions. The virus can also be transmitted through B19V infected blood products, transplant material, and from mother-to-foetus during pregnancy (CDC).

B19V infection commonly occurs in childhood, but can occur in some adults that have not been previously exposed to the virus. In healthy individuals, B19V causes erythema infectiosum, a typically mild disease, also known as ‘fifth disease’. The disease is characterised by a facial rash, which can later appear on the trunk and limbs, and is associated with mild fever and cold-like symptoms. In some adult cases, patients may present with joint pain and swelling that can continue for several months. Other symptoms of B19V infection include anaemia in immunocompromised patients, and a transient decrease in erythropoiesis in cases of sickle-cell anaemia (Rogo, LD. et al).

Diagnosis of B19V infection is generally performed using enzyme-linked immunosorbent assays, or ELISAs, to detect B19V-specific IgM or IgG antibodies in patient sera. Currently, there is no licenced vaccine available or specific antiviral therapy for the treatment of B19V infection.

References

  1. Centers for disease control and prevention: Parvovirus and Fifth disease
  2. Rogo, LD et. al. (2014). Human parvovirus B19: a review. Acta Virol.58:199-213.

Parvovirus Antigens

Parvovirus VP2 protein is a unique reagent that has been developed in response to the need for a highly pure and correctly assembled parvovirus antigen.

Parvovirus VP2 is produced in the form of virus-like particles (VLP) in human cell lines using state-of-the-art expression techniques. Concentration and purification are then performed by a series of ultracentrifuge and precipitation methods, which result in VLPs of exceptional quality and purity.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

Diagnosing HIV in resource-limited settings

In this blog, we discuss the need for improved point-of-care (PoC) diagnostics for HIV and present the virus's cellular mechanism to illustrate our new range of HIV antigens and antibodies. HIV in the developed world On June 5th 1981 in Los Angeles, California, 5...

Our Product Pipeline

If you’ve been following us on social media recently, you might have noticed that we’ve been releasing a lot of new antigens and antibodies. In this blog, we explain how we use the WHO R&D Blueprint to guide our product development and present some highlights from...

From Outbreak to Epidemic: A Short History of The Ebola Virus

In the first of a two-part series, we discuss the history of the Ebola virus up to the ongoing outbreak in the Democratic Republic of Congo, and why this disease has been so challenging to fight. The 2014/15 epidemic In the summer of 2014, the world watched as the...

ELISA Formats for Infectious Disease Diagnostics

The field of diagnostics is rapidly developing, yet ELISA and PCR methods remain the most commonly used techniques in the diagnosis of bacterial and viral infections. In this blog, we discuss the advantages of using serological methods over molecular, PCR-based...

The world’s most extensive range of NS1-specific antibodies for flavivirus research

The Native Antigen Company first gained prominence in 2016, when it developed highly pure Zika virus NS1 protein during the 2015/2016 epidemic. Since then, the company has developed an extensive range of highly specific antigens, antibodies and immunoassays for...

Get in Touch

We sometimes send exclusive information and offers to our customers - please let us know if you are happy to receive these

8 + 11 =

Live Customer Feedback

Join our mailing list

* indicates required